- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ofatumumab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 562 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 25
- States / cities
- Fullerton, California • Aurora, Colorado • Newark, Delaware + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
- Interventions
- IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
- Drug
- Lead sponsor
- Indapta Therapeutics, INC.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,007 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
- Conditions
- Secondary Progressive Multiple Sclerosis (SPMS)
- Interventions
- Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
- Interventions
- SUN-627, Placebo
- Drug · Other
- Lead sponsor
- Sundance Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Raleigh, North Carolina • Columbus, Ohio
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Interventions
- estriol, Placebo, Norethindrone, Progestin Placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 889 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
- Conditions
- Multiple Sclerosis
- Interventions
- ELND002, Placebo
- Drug
- Lead sponsor
- Elan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 17
- States / cities
- Berkeley, California • Fresno, California • Newport Beach, California + 14 more
- Conditions
- Multiple Sclerosis
- Interventions
- Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises
- Behavioral
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- East Hanover, New Jersey • Marlton, New Jersey
- Conditions
- B-cell Mediated Autoimmune Disorders
- Interventions
- Azercabtagene zapreleucel (azer-cel)
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Interventions
- TRX319, Bendamustine
- Biological · Drug
- Lead sponsor
- Tr1X, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more